Literature DB >> 20440586

Physical Characterization of 1,3-dipropyl-8-cyclopentylxanthine (CPX).

Timothy McPherson1, Rahul V Manek, William Kolling, Sihui Long, Tonglei Li.   

Abstract

1,3-dipropyl-8-cyclopentylxanthine (CPX) has been shown to stimulate in vitro CFTR activity in F508 cells. Data from a phase I study demonstrated erratic bioavailability and no measurable clinical response to oral CPX. One cause for its poor bioavailability may have been dissolution rate limited absorption, but there is little published physicochemical data on which to base an analysis. The objective of this study was to determine the solubility and solid-state characteristics of CPX. CPX is a weak acid with pKa of 9.83 and water solubility at pH 7.0 of 15.6 microM. Both laureth-23 and poloxamer 407 increased the apparent water solubility linearly with increasing concentrations. CPX exists in two crystal forms, one of which (form II) has been solved. Form II is a triclinic crystal with space group P1 and calculated density of 1.278 g/cm(3). X-ray powder diffraction and differential scanning calorimetry studies (DSC) indicated that CPX crystals prepared at room temperature were mixtures of forms I and II. DSC results indicated a melting point of approximately 195 degrees C for form I and 198 degrees C for form II. Thermogravimetric analysis indicated no solvent loss upon heating. Dynamic water vapor sorption data indicated no significant water uptake by CPX up to 90% RH. Analysis of the data indicates that CPX may not be amenable to traditional formulation approaches for oral delivery.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20440586      PMCID: PMC2902298          DOI: 10.1208/s12249-010-9436-6

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  19 in total

Review 1.  A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals.

Authors:  Marilyn N Martinez; Gordon L Amidon
Journal:  J Clin Pharmacol       Date:  2002-06       Impact factor: 3.126

2.  1,3,8-trisubstituted xanthines. Effects of substitution pattern upon adenosine receptor A1/A2 affinity.

Authors:  R H Erickson; R N Hiner; S W Feeney; P R Blake; W J Rzeszotarski; R P Hicks; D G Costello; M E Abreu
Journal:  J Med Chem       Date:  1991-04       Impact factor: 7.446

3.  Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis.

Authors:  S H Cheng; R J Gregory; J Marshall; S Paul; D W Souza; G A White; C R O'Riordan; A E Smith
Journal:  Cell       Date:  1990-11-16       Impact factor: 41.582

4.  The use of BDDCS in classifying the permeability of marketed drugs.

Authors:  Leslie Z Benet; Gordon L Amidon; Dirk M Barends; Hans Lennernäs; James E Polli; Vinod P Shah; Salomon A Stavchansky; Lawrence X Yu
Journal:  Pharm Res       Date:  2008-01-31       Impact factor: 4.200

5.  A phase I randomized, multicenter trial of CPX in adult subjects with mild cystic fibrosis.

Authors:  Nael A McCarty; Thomas A Standaert; Mary Teresi; Cynthia Tuthill; Janice Launspach; Thomas J Kelley; Laura J H Milgram; Kathleen A Hilliard; Warren E Regelmann; Mark R Weatherly; Moira L Aitken; Michael W Konstan; Richard C Ahrens
Journal:  Pediatr Pulmonol       Date:  2002-02

6.  An integrated model for determining causes of poor oral drug absorption.

Authors:  L X Yu
Journal:  Pharm Res       Date:  1999-12       Impact factor: 4.200

7.  8-Aryl-and 8-cycloalkyl-1,3-dipropylxanthines: further potent and selective antagonists for A1-adenosine receptors.

Authors:  M T Shamim; D Ukena; W L Padgett; O Hong; J W Daly
Journal:  J Med Chem       Date:  1988-03       Impact factor: 7.446

8.  1,3-Dialkyl-8-(p-sulfophenyl)xanthines: potent water-soluble antagonists for A1- and A2-adenosine receptors.

Authors:  J W Daly; W Padgett; M T Shamim; P Butts-Lamb; J Waters
Journal:  J Med Chem       Date:  1985-04       Impact factor: 7.446

9.  Role for phospholipid interactions in the trafficking defect of Delta F508-CFTR.

Authors:  Ofer Eidelman; Shoshana BarNoy; Michal Razin; Jiang Zhang; Peter McPhie; George Lee; Zhen Huang; Eric J Sorscher; Harvey B Pollard
Journal:  Biochemistry       Date:  2002-09-17       Impact factor: 3.162

10.  A1 adenosine-receptor antagonists activate chloride efflux from cystic fibrosis cells.

Authors:  O Eidelman; C Guay-Broder; P J van Galen; K A Jacobson; C Fox; R J Turner; Z I Cabantchik; H B Pollard
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.